Highlights

  • Bubs Australia (ASX:BUB) has secured permanent FDA authorisation for three infant formula products in the United States.
  • The approval gives the company a permanent regulatory pathway into one of the world’s largest and most tightly regulated infant formula markets.
  • Bubs is already represented in more than 10,000 US stores, providing an established retail base from which to pursue further growth.
  • Private-label opportunities, product innovation and deeper retailer relationships could broaden the US strategy over time.

Bubs Australia (ASX:BUB) has reached an important milestone in its transformation from a China-dependent infant nutrition Business into a more US-focused growth platform. On 7 September 2026, the company announced that it had secured permanent regulatory authorisation from the United States Food and Drug Administration for Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential infant formula products.

The authorisation provides Bubs with a permanent pathway to Supply the US infant formula market and confirms that the approved products, Manufacturing systems and supporting scientific evidence satisfy US regulatory requirements covering safety, nutritional adequacy and quality.

The development materially strengthens the company’s US strategy. Bubs has spent several years building distribution across the United States, and permanent FDA authorisation reduces a major regulatory uncertainty around its long-term market access.

A major US milestone

The United States infant formula market is one of the most tightly regulated consumer categories globally, with substantial scientific, manufacturing and regulatory requirements for participation.

According to Bubs Australia (ASX:BUB), the approval places it among a limited group of non-US manufacturers authorised to supply the market. The company also highlighted its position as the only Australian infant formula Brand with permanent FDA authorisation.

That status could be strategically important. Rather than operating under a temporary or transitional market-access framework, Bubs now has a permanent regulatory foundation for its approved portfolio.

Management believes the authorisation will support continued expansion of its branded formula range while creating additional opportunities for product development and broader market participation.

US distribution provides a foundation

The FDA milestone builds on the retail footprint Bubs has already established in the United States. Management said the brand is now represented in more than 10,000 stores nationwide.

That represents a substantial increase from approximately 4,368 US store locations at the beginning of FY26 and 8,646 by the third quarter.

The company’s challenge now shifts from gaining access and expanding distribution to maximising consumer sell-through, strengthening Brand Awareness and improving the Economics of that growing retail base.

Permanent FDA authorisation could also help deepen relationships with major retailers because it provides greater certainty around the long-term availability of Bubs products in the US market.

Private label adds another growth option

One of the more significant strategic elements of the 7 September announcement was the potential for Bubs Australia (ASX:BUB) to evaluate participation in the US private-label infant nutrition market.

Private-label products could provide another route to Volume growth beyond the company’s own branded portfolio, particularly if retailers seek additional supply partners.

Management made clear that any expansion into private label would remain subject to further regulatory, technical and commercial milestones. Nevertheless, permanent FDA authorisation provides the platform from which Bubs can assess that opportunity.

The company also sees scope to broaden product innovation in the United States, giving it potential pathways to extend beyond its existing goat milk, grass-fed and essential formula offerings.

The FY26 reset still matters

The FDA approval strengthens the long-term picture, but it does not erase the operational challenges Bubs experienced during FY26.

In the first half of FY26, Bubs reported Revenue of $55.5 million, up 14% on the prior corresponding period, while EBITDA improved to $4.4 million from $0.5 million a year earlier.

However, on 29 May 2026 the company reduced its full-year guidance. Expected revenue was lowered from $120 million–$125 million to $105 million–$115 million, while EBITDA guidance moved from a profit of $4 million–$6 million to a range of negative $2 million to positive $2 million.

Management attributed the downgrade to supply constraints, product availability issues, higher air-freight costs, competition and logistics disruption.

The FY26 full-year result released on 27 August 2026 showed revenue growth but continued pressure on profitability, reinforcing that Bubs still needs to demonstrate that its larger distribution footprint can translate into dependable earnings.

Why the FDA approval matters

The latest development changes the strategic context around the US business.

Previously, part of the Investment case rested on whether Bubs could convert its expanded US presence into a durable long-term platform. Permanent FDA authorisation now provides much greater certainty around the company’s ability to remain in the market.

It also validates Bubs’ manufacturing systems, product quality and supporting scientific evidence against demanding US regulatory standards.

For investors, this shifts some of the focus away from market-access risk and toward commercial execution. The key questions now concern retailer productivity, consumer demand, supply-chain stability and margins.

Catalysts and risks to watch

Bubs will host an investor webinar on 10 September 2026 to discuss the FDA authorisation and its US growth strategy. That could provide further detail on how management intends to Leverage the approval.

Other important catalysts include deeper retailer relationships, improved sell-through across the US network, new product launches and any progress toward a private-label offering.

The risks remain significant. Infant nutrition is highly competitive, and large multinational brands have established consumer recognition and distribution relationships.

Supply reliability also remains important given the operational disruption seen during FY26. Higher freight and input costs can pressure margins, particularly when rapid growth requires additional inventory and logistics support.

Private-label expansion is also only a potential opportunity at this stage and remains subject to further regulatory, technical and commercial requirements.

The bottom line

Bubs Australia (ASX:BUB) has reached one of the most important milestones in its US expansion strategy. Permanent FDA authorisation for Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential gives the company a durable regulatory pathway into a major global infant formula market.

The approval strengthens the foundation underneath Bubs’ existing network of more than 10,000 US stores and opens additional strategic Options around product innovation and private-label participation.

The next phase is about converting regulatory success into commercial returns. Stronger sell-through, dependable supply, improved margins and sustained cash generation will determine whether permanent US market access becomes the catalyst for a more durable growth story.